Aribio Receives $6 Million Upfront Payment for Exclusive AR1001 Sales Rights from Fosun Pharmaceutical in China

On September 16, Aribio announced that it had received a contract payment of 6 million dollars (approximately 8.3 billion won) from Fosun Pharmaceutical of China for the exclusive sales rights of its oral Alzheimer's disease treatment, AR1001, in the Greater China region.

This payment is an upfront fee under the exclusive license agreement with Fosun Pharmaceutical. An additional remaining contract payment of 8 million dollars (approximately 11 billion won) from Newco Pharma is also scheduled to be received in installments within this year. With the total contract payment secured at 14 million dollars (approximately 19 billion won), the company explained that the uncertainty surrounding the exclusive sales rights agreement for China has been virtually resolved. This is expected to serve as an opportunity to address the controversy over Aribio's corporate value that arose during the merger process with Solux.

Jaejoon Chung, CEO of Aribio, emphasized, "Receiving this contract payment is a signal that Aribio is poised to make a full-fledged leap onto the global stage," adding, "Even in a challenging economic environment, we are ready to continue achieving world-class results in the field of Alzheimer's disease treatments and to write a new chapter as a leader in Korea's bio industry."

Aribio is smoothly conducting a global Phase 3 clinical trial of AR1001 involving 1,535 patients across 13 countries, including the United States, Europe, China, and Korea. With the trial expected to conclude and topline data to be announced in the first half of next year, the inflow of this contract payment is anticipated to enhance international confidence in the clinical data and serve as a positive signal to investors.

A company official stated, "We are currently engaged in in-depth negotiations with multiple global big pharma companies to sign exclusive sales agreements covering the major markets of the United States and Europe around the time of the clinical trial's conclusion in the first half of next year," and emphasized, "The expected contract size is projected to far exceed all agreements signed so far."

The official added, "This will not only be a milestone for Aribio, but also a historic turning point for the entire K-Bio industry."

Aribio is currently pursuing a merger with Kosdaq-listed Solux, with the merger date set for January 20, 2026.

This content was produced with the assistance of AI translation services.